# Glutamatergic Modulation of Motivation Enhancement: A Pilot Feasibility Trial

> **NCT02373124** · PHASE1,PHASE2 · COMPLETED · sponsor: **New York State Psychiatric Institute** · enrollment: 4 (actual)

## Conditions studied

- Cocaine Use Disorders

## Interventions

- **DRUG:** infusion of NMDA antagonist

## Key facts

- **NCT ID:** NCT02373124
- **Lead sponsor:** New York State Psychiatric Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-12
- **Primary completion:** 2016-10
- **Final completion:** 2016-10
- **Target enrollment:** 4 (ACTUAL)
- **Last updated:** 2020-02-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02373124

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02373124, "Glutamatergic Modulation of Motivation Enhancement: A Pilot Feasibility Trial". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02373124. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*